You searched for - Page 241 of 429 - Institute for Bioengineering of Catalonia

November 16, 2020December 28, 2018

3D bioprinted robots

IBEC’s Smart Nano-Bio-Devices group – the institute’s experts in micro- and nanorobots – have used 3D bioprinting to produce ‘biorobots’ made of biological elements such as muscle tissue.

These bio-inspired soft robotic devices could offer many more capabilities for movement and performance – such as real-time bio-sensing, self-organization, adaptability, or self-healing – than existing systems, which use solely artificial materials.

“Bio-inspired soft robotics is an exciting new discipline, as it may help us overcome the limitations of traditional robotic systems, such as flexibility, responsiveness and adaptability,” says Samuel Sanchez, group leader at IBEC and ICREA research professor.

March 22, 2019December 27, 2018

Assistant Administratiu (Ref. AA)

Application Deadline: 10/01/2019
Ref: AA

L’Institut de Bioenginyeria de Catalunya (IBEC) requereix incorporar un/-a assistant administratiu/-va per tal de donar suport administratiu i fer d’enllaç entre els diferents grups de recerca ubicats al Campus UPC Diagonal Besós i la central de l’IBEC ubicada al Parc Científic de Barcelona. Estant ubicat/-da en l’entorn universitari i internacional del Campus UPC Diagonal-Besós portarà a terme activitats multidisciplinàries de suport administratiu.

May 28, 2020December 24, 2018

Two promising avenues in the fight against antibiotic resistance

IBEC’s Bacterial infections: antimicrobial therapies group have published two papers offering new hope in the urgent search for antimicrobials.

“We desperately need antimicrobials,” says Eduard Torrents. “Antibiotic resistance is one of the greatest threats to human health today, and the time is fast approaching when routine procedures will be much more risky.”
Not only have some common infections or illnesses become resistant to the antibiotics usually used to treat them, a really pressing medical problem now is the rapid rise of ‘superbugs’ or multidrug-resistant bacteria, which are immune to almost all of the antibiotics that are currently available.

June 9, 2020December 21, 2018

Third IBEC student wins PIONER prize for thesis

Jemish Parmar from IBEC’s Smart Nano-Bio-Devices group has been awarded a Premi Pioner from CERCA for his Doctoral Thesis “Micromotors for Environmental Applications”.

Since their launch in 2014, the prizes recognize researchers who present a doctoral thesis with results that are clearly aimed at commercial exploitation. The third IBEC winner of one of these prestigious awards, Jemish was honoured alongside the three other winners – from ICFO, CTFC and IGTP – at a ceremony yesterday.

The jury in this fifth edition of the Premis Pioner was made up of Eduard Balbuena (Enterprise Department at UAB), Josep Maria Pujals (IP lawyer at Oficina Ponti), Melba Navarro (Knowledge Transfer Technology Manager at CIMNE Tecnologia), Anna López Lozano (IP expert),

February 9, 2025December 20, 2018

Molecular Bionics

We are chemists, physicists, mathematicians, engineers, biologists who work alongside to design bionic units that mimic specific biological functions and/or introduce operations that do not exist in Nature. We apply … Read more

May 29, 2020December 19, 2018

IBEC project to defy blood-brain barrier awarded in highly competitive call

IBEC group leader Silvia Muro has been granted funding in MINECO’s ‘Explora Ciencia’ and ‘Explora Tecnología’ 2017 call.

It’s the first competitive grant for Silvia and her group since she joined IBEC at the end of 2017, and one of only 97 research projects to be financed out of the 1594 applications submitted – a success rate of only 6%.

The project, ‘Controlling the differential transport of therapeutic cargoes into versus across the BBB (BBB2GATE)’ will aim to develop drug vehicles that can cross the blood-brain barrier using the natural routes that the body’s substances use to circumvent this obstruction.

April 24, 2025December 17, 2018

Jobs

You’ll join a community of outstanding researchers and skilled professionals devoted to conduct excellent interdisciplinary research at the frontiers of engineering and life sciences in order to generate new knowledge … Read more

March 22, 2019December 11, 2018

Project Manager in Research

The Institute for Bioengineering of Catalonia (IBEC), a cutting-edge research center based in Barcelona, is looking for a Project Manager in Research. His/her role will be to oversee and manage the research projects of several research lines, liaising with other sites and institutions across Spain and Europe.

This position is supported by the Spanish Ministry of Economy and Competitiveness within the Severo Ochoa Centres of Excellence Initiative.

May 28, 2020December 10, 2018

Proteins can transfer electrons at a distance

Collaborating IBEC groups have published a study in Nature Communications that reveals that electron transfer can take place while a protein is approaching its partner site, and not only when the proteins are engaged, as was previously thought.

The results open up a new way of thinking about how proteins interact, and can have implications in a better understanding of many processes – such as photosynthesis, respiration and detoxification – in which electron transfer plays an important role.

The relocation of an electron from one chemical entity to another – electron transfer (ET) – doesn’t happen passively: electrons are carried individually by redox proteins.

March 30, 2023December 9, 2018

Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors

The biotechnology company Iproteos, IBEC and the Vall d’Hebron Research Institute (VHIR) are set to develop an innovative treatment to slow down, stop and even reverse the growth of solid tumors, which represent more than 90% of cancer cases.

It’s a family of peptidomimetic drugs based on a totally new anti-tumor action mechanism, the result of several years of research by Pere Roca-Cusachs’ group at IBEC.

The Translational Research Group on Cancer in Children and Teenagers at VHIR will evaluate candidate drugs, developed with Iproteos’ IPROTech technology, in pediatric tumours in vitro and in vivo.